Express News | Cantor Fitzgerald Reiterates Overweight on Biohaven
Biohaven Is Maintained at Overweight by JP Morgan
Biohaven Analyst Ratings
Bullish Biohaven Insiders Loaded Up On US$41.7m Of Stock
Biohaven CEO Vlad Coric Acquires $999,970 in Company Stock
J.P. Morgan Maintains Biohaven(BHVN.US) With Buy Rating, Announces Target Price $68
Strong Buy Rating for Biohaven Ltd. on Troriluzole's Market Potential and Robust Pipeline
Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
Express News | Biohaven Ltd : JP Morgan Raises Target Price to $68 From $55
Express News | Biohaven Ltd: - Enters Underwriting Agreement With J.P. Morgan and Morgan Stanley
Biohaven: Proceeds From Offering Were About $287.5M Before Deductions >BHVN
Sector Update: Health Care Stocks Steady Premarket Tuesday
TD Cowen Maintains Biohaven(BHVN.US) With Buy Rating, Maintains Target Price $55
TD Cowen Sticks to Its Buy Rating for Biohaven Ltd. (BHVN)
Acuity Brands, Nike And 3 Stocks To Watch Heading Into Tuesday
After-hours Movers: IGM Biosciences, Biohaven Pharma, Acadia Realty Trust
Biohaven $250M Spot Secondary; Price Range $47.00-$48.00
Biohaven Announces Proposed Public Offering of Common Shares
Express News | Biohaven Ltd - Trial to Enroll 575 Patients Across 60 U.S. Sites
Express News | Biohaven Initiates Pivotal Trial of Novel Investigational Drug for Treatment of Migraine